Introduction
Materials and methods
Patients
Disease |
N
| Age ± SD | Age related Q
alb
| Leukocyte count/μl | Lactate | OCB | Tau in pg/ml | Aβ in pg/ml | DC |
---|---|---|---|---|---|---|---|---|---|
PDD | 25 | 71 ± 10 | 8.7 | 0.64 ± 0.76 | 1.72 ± 0.36 | 0 | 272 ± 172 | 725 ± 287 | [7] |
PD | 47 | 66 ± 11 | 8.4 | 0.89 ± 1.45 | 1.73 ± 0.34 | 0 | 296 ± 290 | 967 ± 312 | [20] |
MSA-P | 12 | 64 ± 9 | 8.3 | 1.83 ± 3.18 | 1.58 ± 0.13 | 0 | 239 ± 101 | 755 ± 105 | [10] |
MSA-C | 13 | 65 ± 9 | 8.3 | 1.15 ± 1.21 | 1.72 ± 0.33 | 0 | 221 ± 74 | 794 ± 250 | [10] |
PSP | 16 | 69 ± 7 | 8.6 | 0.75 ± 1.32 | 1.79 ± 0.35 | 0 | 244 ± 133 | 636 ± 305 | [19] |
CBD | 5 | 69 ± 9 | 8.6 | 0.80 ± 0.84 | 1.59 ± 0.17 | 0 | 221 ± 91 | 904 ± 282 | [6] |
SCA | 6 | 61 ± 12 | 8.1 | 0.83 ± 0.41 | 1.72 ± 0.29 | 0 | 208 ± 79 | 916 ± 214 | [16] |
MND | 177 | 62 ± 14 | 8.1 | 1.02 ± 1.13 | 1.75 ± 0.23 | 1 | 289 ± 259 | 924 ± 305 | [32] |
AD | 289 | 72 ± 8 | 8.8 | 0.73 ± 2.10 | 1.76 ± 0.31 | 3 | 667 ± 405 | 534 ± 277 | [21] |
FTLD | 28 | 68 ± 9 | 8.5 | 0.50 ± 0.74 | 1.73 ± 0.23 | 0 | 467 ± 318 | 672 ± 233 | [22] |
VD | 13 | 71 ± 8 | 8.7 | 1.00 ± 0.71 | 1.84 ± 0.14 | 0 | 275 ± 153 | 683 ± 162 | [36] |
HD | 31 | 55 ± 18 | 7.7 | 1.19 ± 1.70 | 1.59 ± 0.39 | 0 | – | – | [13] |
MD | 20 | 57 ± 20 | 7.8 | 3.00 ± 9.50 | 1.70 ± 0.60 | 1 | – | – | – |
CON | 83 | 53 ± 18 | 7.5 | 1.28 ± 2.92 | 1.73 ± 0.34 | 0 | – | – | – |
Analytical procedures
Evaluation of CSF parameters
Statistics
Results
Frequency and extent of intrathecal Ig synthesis and OCB
Frequencies of blood–CSF barrier dysfunction
Outliers of CSF–blood barrier dysfunction
Lactate levels and white cell count
-
0–15 years: 1.1–1.8 mmol/l (9.9–16.2 mg/dl)
-
16–50 years: 1.5–2.1 mmol/l (13.5–18.9 mg/dl)
-
>51 years: 1.7–2.6 mml/l (15.3–23.4 mg/dl)